--Claim 21.   The pure peptide produce of claim 20, wherein said peptide product is derived from a primate source.--

--Claim 22.   The pure peptide product of claim 20, wherein said product is derived from a murine source.--

--Claim 23.   The pure peptide product of claim 20, wherein said product is derived from a porcine source.--

--Claim 24.   The pure peptide product of claim 20, wherein said product is derived from an equine source.--

--Claim 25.   The pure peptide product of claim 20, wherein said product is derived from a bovine source.--

R E M A R K S

The present Preliminary Amendment amends claims 1 and 3 and adds new claims 20-25, so that claims 1-25 are now pending in the application.

The above amendments do not incorporate new matter into the application. In this regard, the amendments are made in order to correct minor grammatical errors in the application and to more specifically set forth what applicants regard as their invention.

It is noted that support for newly added claims 20-25 may be found in the present application at pages 11 and 12, among other places. Based upon the above considerations, entry of the present amendment is respectfully requested.

The Examiner is additionally directed to the accompanying reference by Yoshimura et al, FEBS Letters, Volume 244, pages 487-493 (1989). This reference is listed on Form PTO-1449, which is enclosed herewith.

The Yoshimura et al reference pertains to Human Monocyte Chemoattractant Protein-1 (MCP-1), and its relevancy may be ascertained upon a review thereof. The Examiner is respectfully requested to make this reference of record in the above-identified application.

Please charge any fees or credit any overpayment pursuant to 37 C.F.R. 1.16 or 1.17 to Deposit Account Number 02-2448.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH

By : _A. Murphy Jr._
Gerald M. Murphy, Jr.
Reg. No. 28,977
POB 747
Falls Church, Virginia 22046-0747

703/241-1300

GMM/JWB:bmp
Enclosure - PTO-1449 and reference listed thereon
(1173-145P)

4